Treatment of chronic lymphocytic leukemia

被引：11
作者：
Ferrajoli, A [1 ]
O'Brien, SM [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 02期
关键词：
D O I：
10.1053/j.seminoncol.2004.02.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 65
页数：6
相关论文
共 43 条
  • [1] Infections in patients with chronic lymphocytic leukemia treated with fludarabine
    Anaissie, EJ
    Kontoyiannis, DP
    O'Brien, S
    Kantarjian, H
    Robertson, L
    Lerner, S
    Keating, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) : 559 - 566
  • [2] [Anonymous], 1990, Blood, V75, P1422
  • [3] [Anonymous], 1994, Leuk Lymphoma, V13, P449
  • [4] In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
    Bellosillo, B
    Villamor, N
    Colomer, D
    Pons, G
    Montserrat, E
    Gil, J
    [J]. BLOOD, 1999, 94 (08) : 2836 - 2843
  • [5] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    Byrd, JC
    Peterson, BL
    Morrison, VA
    Park, K
    Jacobson, R
    Hoke, E
    Vardiman, JW
    Rai, K
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2003, 101 (01) : 6 - 14
  • [6] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    Byrd, JC
    Murphy, T
    Howard, RS
    Lucas, MS
    Goodrich, A
    Park, K
    Pearson, M
    Waselenko, JK
    Ling, G
    Grever, MR
    Grillo-Lopez, AJ
    Rosenberg, J
    Kunkel, L
    Flinn, IW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2153 - 2164
  • [7] ELIAS L, 1993, LEUKEMIA, V7, P361
  • [8] Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Faderl, S
    Thomas, DA
    O'Brien, S
    Garcia-Manero, G
    Kantarjian, HM
    Giles, FJ
    Koller, C
    Ferrajoli, A
    Verstovsek, S
    Pro, B
    Andreeff, M
    Beran, M
    Cortes, J
    Wierda, W
    Tran, N
    Keating, MJ
    [J]. BLOOD, 2003, 101 (09) : 3413 - 3415
  • [9] Phase II study of alerntuzurnab in chronic lymphoproliferative disorders
    Ferrajoli, A
    O'Brien, SM
    Cortes, JE
    Giles, FJ
    Thomas, DA
    Faderl, S
    Kurzrock, R
    Lerner, S
    Kontoyiannis, DP
    Keating, MJ
    [J]. CANCER, 2003, 98 (04) : 773 - 778
  • [10] Ferrajoli A, 2001, EXPERT OPIN BIOL TH, V1, P1059
12345